What Is GHRP-2?

Arvat et al. (J. Clin. Endocrinol. Metab.): GHRP-2 produces the strongest GH response among tested GHRPs in healthy adults, with dose-dependent effects and moderate prolactin/cortisol elevation.

Clinical validation of GHRP-2 (Pralmorelin) as a diagnostic GH provocative test in Japan, showing reliable, reproducible GH stimulation for diagnosing adult GH deficiency.

Frieboes et al.: GHRP-2 enhances slow-wave sleep and amplifies nocturnal GH pulses in healthy young men, supporting pre-bed dosing protocols.

Bowers et al.: Chronic GHRP-2 administration in elderly subjects increases IGF-1, GH, and lean body mass while reducing fat mass.

A 2026 study found that long COVID patients exhibited delayed hormonal responses to gonadotropin-releasing hormone, while growth hormone responses to GHRP-2 stimulation remained preserved. These findings suggest functional secondary hypothalamic dysfunction rather than irreversible primary pituitary injury.

In a 2026 study, researchers demonstrated that cynomolgus monkeys exhibit diurnal growth hormone variations similar to humans and respond significantly to exogenous GHRH. These findings confirmed that morning GHRH stimulation reliably assesses growth hormone levels, validating this animal model for pituitary toxicity research.

A 2025 case report demonstrated that a growth hormone-releasing peptide-2 (GHRP-2) load test helped diagnose sudden isolated ACTH deficiency in a patient experiencing severe hypoglycemia. The peptide was utilized alongside other stimulation tests to evaluate specific pituitary functions.

A 2025 study found that the average peak secretion values for ACTH and GH in human patients were 97.2 pg/mL and 25.1 ng/mL, respectively. These findings established critical benchmarks for determining safe cell dosages in future regenerative pituitary transplantations.

A 2025 study found that GHRP-2 decreased M1 macrophage polarization and improved histologic and biomechanical tendon-bone healing properties in a rat rotator cuff tear model. The peptide demonstrated increased bone mineral density, maximal failure load, and stiffness at the healing interface.

A 2024 retrospective study found that GHRP-2 elicited a robust growth hormone response in adolescents with idiopathic growth hormone deficiency and short stature. The findings demonstrated that current diagnostic cut-off levels for the GHRP-2 test may miss some patients and require revisiting.

A 2023 text-mining analysis identified growth hormone-releasing peptide 2 among the top biological concepts linking COVID-19 to resistant hypertension. The study mapped these connections to physiological themes including altered endocrine function, inflammation, and lipid metabolism.

A 2023 study found that adrenocortical function significantly correlated with growth hormone responses to the GHRP-2 test in 65 elderly patients. The research demonstrated that this peptide test may help assess anterior pituitary reserve capacity in individuals with pituitary tumors.

A 2022 study demonstrated that the GHRP-2 test accurately screens for secondary adrenal insufficiency in patients with hypothalamic-pituitary disorders. Researchers found that combining ACTH response and peak cortisol levels during the test yielded 100% specificity and high diagnostic accuracy.

Pharmacological agents including Growth Hormone Releasing Peptide-2 (GHRP-2), steroids, and SARMs were identified as potential options for managing cachexia. A 2022 review investigated these treatments, noting their ability to target inflammation and muscle wasting despite a lack of standardized recommendations.

A 2022 study found a negative synergistic effect between overweight status and tumor size on growth hormone secretion in patients with non-functioning pituitary tumors. Researchers demonstrated that overweight individuals exhibited a significantly higher prevalence of severe growth hormone deficiency during GHRP-2 testing.

A 2021 case report found that a patient presenting with chronic fatigue syndrome actually had combined adrenocorticotropin and growth hormone deficiency. The study demonstrated that utilizing a growth hormone-releasing peptide-2 test successfully identified the deficiency, leading to symptom amelioration following hormone replacement.

Intravascular large B-cell lymphoma with pituitary involvement predominantly occurs in older women and often presents with reversible panhypopituitarism, a 2021 case report found. Researchers demonstrated that ICAM1-negative lymphoid cells may extravasate into pituitary tissues.

A 2021 case report found that a GHRP-2 assay elicited an excessive basal growth hormone reaction in a patient with a gastrointestinal stromal tumor and refractory hypoglycemia. The study demonstrated that the hypoglycemia resolved following dexamethasone administration and surgical resection.

A 2021 study demonstrated that dried blood spot sampling successfully detected GHRP-2 up to four hours after a single intravenous dose. The validated method established a limit of detection of 50 pg/ml and confirmed long-term sample stability for over two years.

In a 2021 virtual screening study, researchers identified pralmorelin, several antiviral drugs, and 20 novel compounds as potential inhibitors of the SARS-CoV-2 main protease. The study demonstrated that these molecules exhibit promising interactions with the target protein, providing hits for further antiviral development.